双侧风险降低乳房切除术联合乳房再造的高危乳腺癌患者队列的手术结局指标
该队列研究纳入445例终生乳腺癌风险大于25%并接受双侧风险降低乳房切除术联合乳房再造的女性,比较围手术期确诊乳腺癌组与良性组的手术结局;癌症组完成再造所需计划手术更多,急诊手术、非计划手术及再造后并发症率两组相似,自体重建翻修率低于假体重建。
要点
- 癌症组完成再造所需计划手术多于良性组(4次 vs 2次,P=0.002)。
- 两组急诊手术、非计划手术及再造后并发症率相似,总体约五分之一需翻修手术。
- 自体重建翻修率为1.24/1000人年,假体重建为2.52/1000人年。
核心结论
- 考虑风险降低乳房切除术的女性可被告知该手术安全有效,但可能需多次干预,该信息应纳入知情同意。
研究设计与样本
- 队列研究,纳入445例终生乳腺癌风险大于25%并接受双侧风险降低乳房切除术联合乳房再造的女性,按围手术期是否确诊乳腺癌分为癌症组与良性组,比较手术结局。
主要发现
- 中位随访时间良性组70个月,癌症组73个月。
- 癌症组年龄大于良性组(43岁 vs 39岁,P<0.001)。
- 癌症组完成再造所需计划手术多于良性组(4次 vs 2次,P=0.002)。
- 两组急诊手术、非计划手术(如包膜切除术)及再造后并发症率相似。
- 总体约五分之一女性需翻修手术;自体重建翻修率为1.24/1000人年,假体重建为2.52/1000人年。
临床怎么用
- 作者认为,考虑风险降低乳房切除术的女性可被告知该手术安全有效但可能需多次干预,该信息应纳入知情同意。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women with breast cancer-related genetic pathogenic variants (e.g., BRCA1 , BRCA2 ) or with a strong family history carry lifetime risks of developing breast cancer of up to 80 to 90 percent. A significant proportion of these women proceed to bilateral risk-reducing mastectomy. The authors aimed to document the surgical morbidity of risk-reducing mastectomy and establish whether a diagnosis of breast cancer at the time of surgery impacted outcomes. METHODS: Clinical details of 445 women identified as having a greater than 25 percent lifetime risk of developing breast cancer who underwent risk-reducing mastectomy and breast reconstruction were interrogated for surgical outcomes such as planned, unplanned, and emergency procedures; complication rates; length of stay; and longevity of breast reconstruction. These outcome measures were recorded in women diagnosed with breast cancer perioperatively (cancer group) and those without malignancy (benign group). RESULTS: Median follow-up was similar in both groups (benign group, 70 months; cancer group, 73 months). Patients were older in the cancer group than in the benign group (43 years versus 39 years; p < 0.001). Women in the cancer group required more planned procedures to complete reconstruction than those in the benign group (four versus two; p = 0.002). Emergency procedures, unplanned surgical interventions (e.g., capsulectomy), and postreconstruction complication rates were similar between groups. One in five women overall required revision surgery. Patients with autologous reconstructions had a revision rate of 1.24 per 1000 person-years compared with 2.52 per 1000 person-years in the implant reconstruction group. CONCLUSIONS: Women contemplating risk-reducing mastectomy can be reassured that this is a safe and effective procedure but will likely take multiple interventions. This knowledge should be integral to obtaining informed consent. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, II.
引用
- Gandhi A, Duxbury P, Clancy T, et al. Surgical Outcome Measures in a Cohort of Patients at High Risk of Breast Cancer Treated by Bilateral Risk-Reducing Mastectomy and Breast Reconstruction. Plast Reconstr Surg. 2022. PMID: 35749222. doi:10.1097/PRS.0000000000009383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。